Enforcement Report - Week of November 29, 2023
LA JOLLA, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...
WARREN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current...
Riluzole, a drug approved to treat amyotrophic lateral sclerosis(ALS), a disease affecting nerve cells controlling movement, could slow the gradual loss of a particular brain cell that occurs in Niemann-Pick disease type C1n(NPC1), a rare genetic disorder affecting children and adolescents, suggests a study in mice by scientists at the National Institutes of Health.
Mitsubishi Tanabe Pharma Announces EXSERVAN is Now Available in the U.S.
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that EXSERVAN™ (riluzole), the first oral film formulation of riluzole, is now available in the U.S. for the treatment of amyotrophic lateral sclerosis (ALS). EXSERVAN, which dissolves on top of the tongue, was developed to help meet the needs of people with ALS, including those who have difficulty swallowing some medications.1,2,3
JERSEY CITY, N.J. and WARREN, N.J., Jan. 21, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S. rights to commercialize EXSERVAN™ (riluzole), an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis (ALS).
Standard Chem`s Generic Riluzole Receives Approval in US
Shares of specialty pharmacy company Aquestive Therapeutics are up more than 18% in premarket trading following a late Friday afternoon approval from the U.S. Food and Drug Administration (FDA) for Exservan, a treatment for amyotrophic lateral sclerosis.
WARREN, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that it granted a license to Zambon S.p.A. for the development and commercialization of Riluzole Oral Film (ROF) in the European Union for the treatment of amyotrophic lateral sclerosis (ALS). Zambon is a multinational pharmaceutical company strongly committed to innovating cure and care to make patients’ lives better, with a focus on the central nervous system (CNS) therapeutic area.